19
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The overexpression of p16 is not a surrogate marker for high-risk human papilloma virus genotypes and predicts clinical outcomes for vulvar cancer

      research-article
      , ,
      BMC Cancer
      BioMed Central
      Vulvar cancer, vSCC, HPV, p16, Prognosis

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          We aimed to evaluate the correlation between p16 ink4a-overexpression and high risk (hr)HPV-DNA in vulvar squamous cell carcinoma (vSCC) tumors as well as the impact of both biomarkers on the prognosis of vSCC patients.

          Methods

          PCR-detection of (hr)HPV-DNA and immunohistochemical staining for p16 ink4a were conducted in 85 vSCC tumors. Survival analyses included the Kaplan–Meier method, log-rank test and Cox proportional hazards model.

          Results

          p16 ink4a-overexpression and (hr)HPV-DNA were detected in 35 and 37 of the 85 tumors, respectively. Among the 35 p16 ink4a-positive tumors, 10 lacked (hr)HPV-DNA (29 %). Among the 50 p16 ink4a-negative tumors, (hr)HPV-DNA was detected in 12 cases (24 %). The median follow-up was 89.20 months (range 1.7–189.5 months). P16 ink4a-overexpression, but not (hr)HPV-DNA positivity of the primary tumor, was correlated with prolonged overall survival (OS) ( p = 0.009). P16 ink4a-overexpression predicted a better response to radiotherapy ( p < 0.001). Univariate analysis has demonstrated that age ( p = 0.025), tumor grade ( p = 0.001), lymph node metastasis ( p < 0.001), FIGO stage ( p < 0.001), p16 ink4a-overexpression ( p = 0.022), and adjuvant RTX ( p < 0.001) were prognostic factors for OS. Multivariate analysis has demonstrated that lymph node metastasis (HR 1–2.74, 95 % CI 1.50–5.02, p = 0.019), tumor grade (HR 1–2.80, 95 % CI 1.33–5.90, p = 0.007) and p16 ink4a-overexpression (HR 1–2.11, 95 % CI 1.13–3.95, p = 0.001) are independent prognostic factors.

          Conclusion

          The discovered overlap suggests the use of p16 ink4a in combination with HPV-DNA detection as an ancillary test for future research and clinical studies in vSCC. The prognostic and predictive value of p16 ink4a-overexpression should be tested in larger cohort studies.

          Electronic supplementary material

          The online version of this article (doi:10.1186/s12885-016-2503-y) contains supplementary material, which is available to authorized users.

          Related collections

          Most cited references26

          • Record: found
          • Abstract: not found
          • Article: not found

          Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            p16(Ink4a) overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors.

            p16(Ink4a) is a protein involved in regulation of the cell cycle. Currently, p16(Ink4a) is considered a tumor suppressor protein because of its physiological role and downregulated expression in a large number of tumors. Intriguingly, overexpression of p16(Ink4a) has also been described in several tumors. This review attempts to elucidate when and why p16(Ink4a) overexpression occurs, and to suggest possible implications of p16(Ink4a) in the diagnosis, prognosis and treatment of cancer.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck.

              A subset of head and neck cancers is associated with the human papillomavirus (HPV). Viral infection is closely correlated with expression of p16(INK4A) in these tumors. We evaluated p16(INK4A) as a prognostic marker of treatment response and survival in a well-defined and prospectively collected cohort of patients treated solely with conventional radiotherapy in the Danish Head and Neck Cancer Group (DAHANCA) 5 trial. Immunohistochemical expression of p16(INK4A) was analyzed in pretreatment paraffin-embedded tumor blocks from 156 patients treated with conventional primary radiotherapy alone. The influence of p16(INK4A) status on locoregional tumor control, disease-specific survival, and overall survival after radiotherapy was evaluated. p16(INK4A) positivity was found in 35 tumors (22%). Tumor-positivity for p16(INK4A) was significantly correlated with improved locoregional tumor control (5-year actuarial values 58% v 28%; P = .0005), improved disease-specific survival (72% v 34%; P = .0006), and improved overall survival (62% v 26%; P = .0003). In multivariate analysis, p16(INK4A) remained a strong independent prognostic factor for locoregional failure (hazard ratio [HR], 0.35; 95% CI, 0.19 to 0.64), disease-specific death (HR, 0.36; 95% CI, 0.20 to 0.64), and overall death (HR, 0.44; 95% CI, 0.28 to 0.68). Expression of p16(INK4A) has a major impact on treatment response and survival in patients with head and neck cancer treated with conventional radiotherapy.
                Bookmark

                Author and article information

                Contributors
                +48583493190 , jacek.sznurkowski@gumed.edu.pl
                zawrocki@gumed.edu.pl
                biernat@gumed.edu.pl
                Journal
                BMC Cancer
                BMC Cancer
                BMC Cancer
                BioMed Central (London )
                1471-2407
                13 July 2016
                13 July 2016
                2016
                : 16
                : 465
                Affiliations
                [ ]Department of Surgical Oncology, The Medical University of Gdańsk, ul. Smoluchowskiego 17, 80-214 Gdańsk, Poland
                [ ]Department of Pathology, The Medical University of Gdańsk, ul. Smoluchowskiego 17, 80-214 Gdańsk, Poland
                Article
                2503
                10.1186/s12885-016-2503-y
                4944532
                27411473
                45e12b65-3572-47c1-bf23-817646f78f3b
                © The Author(s). 2016

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 30 December 2015
                : 5 July 2016
                Funding
                Funded by: Polish Ministry of Science and Higher Education
                Award ID: N 40306631/3077
                Award Recipient :
                Funded by: Polish National Center of Science
                Award ID: 2012/07/B/N25/00018
                Award Recipient :
                Categories
                Research Article
                Custom metadata
                © The Author(s) 2016

                Oncology & Radiotherapy
                vulvar cancer,vscc,hpv,p16,prognosis
                Oncology & Radiotherapy
                vulvar cancer, vscc, hpv, p16, prognosis

                Comments

                Comment on this article